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ABSTRACT 
 
Background. Atherosclerosis is a chronic, multifactorial pathology caused by 
long exposure to cardiovascular risk factors. Risk factors provoke oxidative 
stress and endothelial dysfunction, leading to expression of adhesion 
molecules, diapedesis of monocytes and transformation into macrophages. 
Macrophages internalize oxidized-LDL, become foam cells and release 
proinflammatory cytochines that increase atherosclerosis and 
metalloproteases that destabilize the plaque. 
High plasma aldosterone level (PAC) was shown to predict short and long-
term mortality and life-threatening arrhythmias in patients with myocardial 
infarction (AMI) and a prognostic role was attributed to PAC also in stable 
coronary artery disease (CAD) patients. Moreover, mineralocorticoid 
receptor antagonism (MRA) was demonstrated to reduce cardiovascular 
(CV) mortality in patients with heart failure (HF) or left ventricular dysfunction 
post-acute AMI. Recent clinical trials demonstrated a direct aldosterone pro-
atherogenic or plaque-destabilizing effect, supported by the recent 
identification of pathways linking aldosterone to oxidative stress and 
metalloproteinase-9 (MMP-9) activation, which we postulate might occur in 
monocytic/macrophagic cells, recognized effectors of plaque instability and 
ensuing CV events. 
 
Aim. The primary aim of our study was to investigate the effects of 
aldosterone and mineralocorticoid receptor antagonist on the MMP-9 
production by monocytes/macrophages 
 
Material and Methods. We employ a THP-1 monocytic cell-line and human 
monocytes from blood of healthy donors; to obtain macrophages, we used 
phorbol myristate acetate (PMA) for the cell line and GM-CSF for human 
cells.  
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We first confirmed the cell transition by FACS and gene expression of PPARγ 
gene. 
Cells were investigated for the presence of the Mineralocorticoid Receptor 
(MR) at Western Blot and RT-PCR and to elucidate the effects of aldosterone 
on these cells we analyzed FKBP51 gene expression. The effect on MMP-9 
expression and activity, was assessed by RT-PCT and zimography, 
respectively. 
 
Results. We demonstrated that macrophages, both THP-1 and human,  
express an higher amount of PPARγ mRNA, confirming the successful 
phenotypic transition. 
Macrophages express also an higher amount of MR protein and mRNA  
respect to monocytes, thus explaining the non-responsiveness of monocytes 
to aldosterone in MMP-9 increase. On the contrary, THP-1 macrophages 
(differentiated after 72 hours in PMA 100nM), showed in the dose and time-
dependent curve, a significant MMP-9 activity  in response to aldosterone in 
particular at lower concentrations (10-8 and 10-9M) between 16 and 48 
hours. Responsiveness of macrophages to aldosterone was confirmed by 
FKBP51 gene expression. 
We repeated the dose and time-response curve in human cells: MMP-9 gene 
expression was significantly higher after 2 hours of aldosterone at 10-7M and 
10-8M (2,03 ± 0,26 and 2,05 ± 0,26 fold change vs. control, respectively; p < 
0.001) and at 6 hours only aldosterone at 10-7M, while MMP-9 activity 
increases only at 24 hours in presence of aldosterone 10-8 M aldosterone 10-9 
M (1,23 ± 0,07 and 1,36 ± 0,08 respectively). In presence of canrenone as MR 
inhibitor, RT-PCR shows a clear trend in reduction both at 2 and 6 hours in 
presence of canrenone respect to aldosterone-induced MMP-9 gene 
expression, even if not significant (p = 0.08 at 6 hours). 
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INTRODUCTION 
 
Coronary artery disease  
 
Definition 
Cardiovascular disease (CVD) is the most common heart disease and cause 
of death (17.3 million deaths per year) and represented the 30% of global 
deaths in 2008{{9008 Mozaffarian,D. 2015}}.  Myocardial infarction is a 
common manifestation of ischemic heart disease, a condition in which 
interruption of blood supply to a region of the heart results in ischemia and 
subsequent cell death{{9042 He,B.J. 2013}}.  The main cause of CVD is the 
coronary heart disease (CHD), also called coronary artery disease (CAD) that 
includes numerous problems, many of which are related to a process called 
atherosclerosis. Atherosclerosis is a type of arteriosclerosis, a general term for 
the thickening and hardening of arteries. This condition is rarely fatal, but 
thrombosis, superimposed on a ruptured or eroded atherosclerotic plaque, 
may cause a heart attack or stroke{{8966 Falk,E. 2006}}.  Between the heart 
disease, stroke is the second global cause of death.  
Other types of cardiovascular disease are hypertensive heart disease, 
arrythmia, heart valves problems and heart failure. 
CAD is a progressive disease that generally begins in childhood and 
manifests clinically during the mean and the elderly ages{{9009 Rosamond,W. 
2008; 9010 Lloyd-Jones,D. 2010}}.  Atherosclerosis is a chronic inflammatory 
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disease of the arterial wall in response to chronic multifactorial injuries that 
lead to the formations of fibrous plaques (atheromas) in the coronary arteries, 
that are composed of fibrous tissues, cells and lipids{{9012 Buja,L.M. 2012}}.   It 
becomes clinically clear when the plaque limits the blood flow under 
increased requirement{{8967 Maiolino,G. 2015}}. 
 
Risk Factors 
The American Heart Association periodically evaluated the cardiovascular 
health of the nation by tracking seven key factors and behaviours that 
increase risks for heart disease and stroke; the goal is to improve the 
cardiovascular health of all Americans by 20 percent and reduce deaths 
from cardiovascular diseases and stroke by 20 percent, by the year 2020.  
The risk factors are multiple and belong to lifestyle and biochemical and 
physiological area: behaviour as smoking, physical inactivity, excess of 
alcohol and fat diet stress leading to obesity, are considered as risk factors, 
alongside high plasma cholesterol, high blood pressure, low plasma HDL-
cholesterol, high plasma triglyceride, diabetes mellitus, thrombogenic factors, 
age, gender and family history. 
Life’s Simple 7 are: not smoking, physical activity, healthy diet, body weight, 
and control of cholesterol, blood pressure and blood sugar.  
CVD risk factors are commonly divided, from the operative standpoint, as 
non-modifiable and modifiable. 
Non-modifiable risks factors: 
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Sex and age. There is an excess of cardiovascular risk for men than in women 
before menopause, and progressively increases in women, especially above 
55 years; the protection of fertile women is due to the “umbrella-oestrogens”-
effect that leads to a more favourable lipid profile. 
Figure 1. Prevalence of coronary heart disease by age and sex{{9008 
Mozaffarian,D. 2015}}.   
 
Family history of CVD is another known risk factor attributable to the 
transmission of other risk factors, such as hyperlipidaemia, diabetes, 
hyperhomocysteinemia, some of which are still to be discovered, as recently 
shown by the identification of the MEF2A mutation (Topol, Wang; Colonna, 
Rossi JCVP) 
Partially modifiable risk factors: 
Hypercholesterolemia is one of the most important risk factors and it is strictly 
associated with endothelial dysfunction because oxidized-LDLs are mediators 
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of endothelial damage. About 43 percent of Americans have total 
cholesterol higher of 200 mg/dL, but this factor alone is not sufficient to cause 
the disease, as shown by the fact that patients hospitalized for acute 
coronary syndrome, 50% have normal LDL values{{8968 Sachdeva,A. 2009}}. 
 
 
 
 
 
Hypertension. About 33 percent U.S. adults have high blood pressure and 
about 77 percent of them are using antihypertensive medication. 
Notwithstanding this, only 54 of them have their condition controlled.  This 
rate would be much lower if the target blood pressure matches for systolic 
blood pressure that were identified in the recently published SPRINT study, 
Figure 2. Estimated 10-year coronary heart disease risk in adult 55 
years of age according to levels of various risk factors 
(Framingham Heart study){{9008 Mozaffarian,D. 2015}}. 
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e.g. 120 systolic, were adopeted (). Hypertension produce hemodynamic 
stress on the arterial wall that promotes oxidative processes. 
Diabetes mellitus. Insulin normally lowers the free fatty acids plasma 
concentration and its lack of effect favours the increase, in diabetic patients. 
In the presence of high concentrations of glucose, lipoproteins may be 
modified by glycation (non-enzymatic glycosides), which alters the 
recognition and binding by the receptors.  The prevalence of diabetes for 
adults worldwide was estimated to be 6.4 percent in 2010 but diabetes rates 
are growing: in fact, about 35 percent of Americans have pre-diabetes. 
Obesity/Overweight. Most Americans older than 20, about 69 percent, are 
overweight or obese, and about 32 percent children are overweight or 
obese.  Obesity enhances all the diseases associated with it, such as diabetes 
type II, dyslipidaemia and hypertension and low level of adiponectin. 
Modifiable risk factors: 
Smoking. In 2010 worldwide, tobacco smoking (including second hand 
smoke) was one of the top three leading risk factors for disease and 
contributed to an estimated 6.2 million deaths. 
Smoking stresses the vasculature, decreases coronary blood flow and 
myocardial oxygen delivery, increases activation of leukocytes and platelets, 
blood pressure and insulin resistance.  
The reactive oxygen species of the cigarettes directly causes endothelial 
damage and indirectly affect lipid peroxidation. 
The endothelial dysfunction associated to smoke (Brunner, JH Guidelines…) is 
related with the decreasing activity of eNOS, enhanced expression of 
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adhesion molecules and deregulation of the local thrombotic balance.  
Studies demonstrated dose-related impairment of endothelium-dependent 
vasodilatation in smokers’ circulation. 
Unhealthy diet. Less than 1 percent of U.S. adults and no children meet the 
American Heart Association’s definition for “Ideal Healthy Diet.”  Of the 5 
components of a healthy diet, reducing sodium and increasing whole grains 
are the biggest challenges. 
 
 “Non traditional” risk factors are acquiring increasing importance as 
emerging risk predictors: C-reactive protein (CRP), lipoprotein associated 
fosfolipase A2 (Lp-PLA2), fibrinogen, and homocysteine. These risk predictors 
were selected because substantial evidence is accumulating of their 
predictive abilities, there is a genetic basis for premature disease, modifying 
treatments are available, and/or these factors are the subject of ongoing or 
completed clinical trials{{8969 Hackam,D.G. 2003}}. 
Between these new risk factors, LpPLA2 is acquiring increasing importance 
because of its role in the degradation of pro-inflammatory phospholipids (like 
ox-LDL) and in the generation of lysophosphatidilcholine (that in turn 
activates endothelial NADPH oxidase) and oxidized free-fatty acid, which are 
pro-atherogenic molecules. High levels of Lp-PLA2 predict CV mortality risk 
and acute myocardial infarction{{8967 Maiolino,G. 2015}}. 
 
Pathogenesis 
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Atherosclerosis affects mostly medium and large-sized arteries and is 
characterized by intramural thickening of the subintima that encroaches 
over the arterial lumen. Its typical lesions are plaques, which are composed 
of three major features: 
1) Cellular component: endothelial cells, leukocytes and intimal smooth 
muscle cells 
2) Connective tissue matrix and extracellular lipids.  
3) Intracellular lipids that accumulate within macrophages, thereby 
converting them into foam cells. 
The most affected sites are the aorta and its main branches, the vessels of the 
cerebral circulation, lower limb and the coronary arteries, where the disease 
affects epicardial arteries causing reduced blood flow reserve in the vessels. 
 
Figure 3: Schematic rapresentation of atherosclerotic plaque progression 
(http://www.carlagoldenwellness.com) 
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If plaques become unstable, because of denudation of the overlying 
endothelium or plaque rupture, a thrombotic occlusion of the overlying artery 
may result.  
 
Early atherosclerotic lesion  
Endothelial cells undergo qualitative changes when subjected to irritative 
stimuli, i.e. hyperlipidaemia, hypertension, and pro-inflammatory cytokines, 
leading to an intact but leaky, activated and dysfunctional endothelium that 
promote the lesion initiation.  Later, endothelial cells may vanish and 
denuded areas appear over advanced lesions, with or without platelets 
adhering to the exposed subendothelial tissue{{8966 Falk,E. 2006}}.  Plasma 
molecules and lipoprotein extravasate through the weak endothelium in the 
subendothelial space; here, lipoproteins are oxidized and become cytotoxic, 
proinflammatory and pro-atherogenic.  
Low-density lipoproteins (LDLs) have a shell of phospholipids, free cholesterol 
and apolipoprotein B100 (ApoB100) with a core of esterified cholesterol and 
triglycerides.  These particles can accumulate in the subendothelial space, 
where the ApoB100 binds to proteoglycans of the extracellular matrix, 
trapping the LDLs.  Under the influence of pro-inflammatory cytokines, these 
cells produce reactive nitrogen and oxygen species (ROS) that oxidize LDLs, 
which play a major role in the initiation and progression of the atherosclerotic 
process. 
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The oxidation step could be mediated by myeloperoxidase, 15-lipoxygenase, 
and/or nitric oxide synthase (NOS){{8966 Falk,E. 2006}};  nitric oxide could be 
produced by endothelium, where it exerts a vasodilator and protective role, 
or, in contrast it is produced by macrophages and it has a pro-atherogenic 
effect. 
The activated endothelium produces and expresses adhesion molecules, 
primarily vascular cell adhesion molecule-1 (VCAM-1), intracellular adhesion 
molecule 1 (ICAM-1), P- and E-selectin which are involved in blood cells 
recruitment recruiting as monocytes and T-cells. 
Once activated, endothelial cells also secrete chemokines, e.g., monocyte 
chemoattractant protein 1 (MCP-1), which attract monocytes and T-cells in 
the subendothelial space, acting on their CCR2 receptor.  Monocytes roll on 
endothelial cells through the interaction of monocyte P-selectin glycoprotein 
ligand-1 (PSGL-1) with endothelial selectins and after firm adhesion to the 
dysfunctional endothelium, a process called diapedesis allows monocytes to 
enter in the subendothelial space. T-cells gain access to the intima with 
similar mechanisms involving chemokines and adhesion molecules. 
Once within the intima, monocyte-derived macrophages may recruit 
themselves by secreting MCP-1; also cytokines as interleukin-8 (IL-8) are 
involved in monocyte-macrophages trafficking. 
Monocyte differentiation into macrophages 
Once in the intima monocytes are stimulated by macrophage colony-
stimulating factor (M-CSF) produced by activated endothelial cells to 
differentiate into macrophage and/or dendritic cell-like features. 
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Foam cells formation 
Oxidation of LDL causes a loss of their affinity for the LDL receptor, which  
furthermore is downregulated by cholesterol intracellular overload, and 
determines a gain of affinity for the scavenger receptors (SR)A and CD36 
which are, in contrast, up-regulated by cholesterol excess in macrophages. 
Thus, upon binding of oxidized LDL (oxLDL), these receptors are internalized 
with consequent foam cells formation.  
Macrophages internalize ox-LDL until they die by (apoptosis and necrosis), 
thus contributing to formation of a soft lipid-rich core within the plaque.   
Then, they produce matrix proteolithic enzyme, mainly metalloproteinases, 
which are able to increase the thrombogenic and destabilizing properties of 
the plaque.  Once internalized by macrophages cholesteryl esters of 
lipoproteins are hydrolyzed to free cholesterol and fatty acids. Free 
cholesterol is then transferred to other cell sites, like endoplasmic reticulum, 
and this lead to downregulation of LDL receptors and cholesterol synthesis 
through inhibition of the sterol-regulatory element binding pathway (SREBP).  
Free cholesterol could also migrate, probably through a Golgi vescicular 
transport to the plasma membrane, where it is removed from the cells by the 
ATP-binding cassette transporter (ABC)A1- and ABCG1-mediated transport to 
apolipoprotein A1 and HDL, respectively, or by ‘‘passive diffusion’’ to 
cholesterol-poor HDL. 
 
Other atheroma cell components 
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With progression of the disease, the immunoinflammatory response is joined 
by a fibro-proliferative response mediated by intimal smooth muscle cells, 
which  proliferate under the stimulus of platelet derived growth factor (PDGF).   
These cells produce extracellular matrix molecules, like collagen and elastin, 
forming the fibrous cap that overlies the atherosclerotic plaque, to confer 
stability and to protect against rupture and destabilization. If the atherogenic 
stimuli persist over years, as they regularly do, the reparative response may 
become so voluminous that lumen is lost, blood flow is reduced, and 
ischemia sets in. 
Figure 4. Putative pathway of oxidized low-density lipoprotein (oxLDL) in the 
atherogenetic process according to the oxidative hypothesis of 
atherosclerosis{{8967 Maiolino,G. 2015}}. 
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Innate Immunity in atherogenensis 
The innate immunity is the first line of defense against pathogens and it is 
characterized by a fast response.  During local inflammation, in the early 
stage of the disease, leukocytes enter a tissue in response to a perceived 
pathogen; in atherosclerotic lesions the nature of the inciting pathogen is not 
completely clear, probably there are many different candidate pathogens.  
The main candidates are the minimally oxidized LDLs and their late form, the 
oxidized LDLs{{8970 Binder,C.J. 2002}} which are themselves directly 
chemotactic for monocytes and T cells and stimulate both cellular and 
humoral response.  Among other biological effects, ox-LDLs (and its various 
oxidized lipid components) are cytotoxic for endothelial cells, for 
macrophages and smooth muscle cells (SMCs) and stimulate the release of 
MCP-1 and of M-CSF from endothelial cells{{8971 Zeiher,A.M. 1991; 8972 
Chatzizisis,Y.S. 2007}}. 
Other candidate pathogens are molecules that trigger the inflammatory 
cascade, such as lysophospholipids or oxidized lipids, and metabolic events 
which lead to increased production of ROS, such as hypercholesterolemia or 
hypertension{{8970 Binder,C.J. 2002}}. 
Monocytes constitute the main component of innate immunity; they are 
involved in exogenous and endogenous inflammation, counteracting 
pathogens and eliminating damaged cells and molecules. One of the most 
known extracellular inducer of macrophage activation is LPS, which binds 
toll-like receptor 4 (TLR-4) triggering different signalling cascades, including 
those mediated by transcription nuclear factor kB (NF-kB), Janus N-terminal 
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kinase (JNK) and p38 kinase{{8974 Barish,G.D. 2005}}. Recruitment of 
monocytes and their differentiation into macrophages are essential for lesion 
formation, as demonstrated in hypercholesterolemic mices deficient in MCP-
1 or in its receptor that showed reduced atherosclerotic lesion{{8973 
Gosling,J. 1999; 9013 Boring,L. 1998}}.  Similar results were obtained in the 
mices lacking of M-CSF{{9014 Smith,J.D. 1995}}.  
Oxidized LDLs and chemokines as MCP-1 increase the chemotaxis of 
monocytes and T cells, but not of neutrophils.  In turn, the expression of MCP-1 
in arterial cells is stimulated by oxidized phospholipids, cytokines, and 
activated complement{{8970 Binder,C.J. 2002}}. 
Macrophages and dendritic-like cells have the capacity to ingest pathogens 
and to initiate adaptive immune responses presenting the antigen; they 
produce ROS, proteases and cytokines against the pathogens and they exert 
scavenging function mediated through pattern recognition receptors (PRR) 
as SR-A and CD36 and Toll-like receptors (TLR) involved in inflammation. CD14 
(the non transmembrane receptor for lipopolysaccharide) initiates the 
inflammatory responses through interaction with TLRs. 
Components of oxLDL can activate macrophages and affect gene 
expression of genes such perixosome-activated receptor-g, CD36 and ATP-
binding cassette transporter A1, which influence macrophage inflammatory 
and atherogenic activity. 
The complement factors are also involved in atherosclerosis, in fact 
deposition of C3,C4 and terminal C5b-C9 occurs in lesions, as well as IgM 
against specific epitopes of ox-LDL{{8970 Binder,C.J. 2002}}. 
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During atherogenesis, monocyte migration into the intima, and subsequent 
differentiation into macrophages, induce production and release of 
cytokines as tumor necrosis factor (TNF), IL-b and IL-6 and several MMPs. 
Differentiated macrophages produce and release MMPs such as MMP-1, -2, -
3, -8, -9 and -14. 
NK cells in CAD patients are lower compared to healthy patients{{8976 
Jonasson,L. 2005}}. 
Macrophage phenotypes in atherosclerosis  
Macrophages exposed to specific micro-environments differentiate into 
heterogeneous range of macrophages, whose diversity can be assessed by 
assessing the expression of numerous surface markers as well as by their 
secretome. 
 
Classically activated M1 macrophages  
The classical M1 activation is driven by interferon-γ (INFγ), inflammatory 
cytokines such as TNF, and microbial products as lipopolysaccharide (LPS). 
The M1 type is an inflammatory cell that increases and sustains inflammation 
secreting pro-inflammatory cytokines such as interleukin-6 (IL-6), IL-1b, TNF, IL-
12, IL-23 and they also produce ROS.  They express chemokine receptors 
(CXCL9, CXCL10, CXCL5) that further promote the recruitment of Th-1 and NK 
cells, to counteract the acute infection provoked by pathogens.  In case of 
chronic induction of M1 macrophages activation, tissue damage and impair 
wound healing occur. 
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Alternatively activated M2 macrophages 
M2 macrophages are considered as anti-inflammatory cells, and they 
counteract the inflammatory response sustained by the M1 type.  They are 
mainly involved in tissue repair and show phagocytic, pro-angiogenic and 
pro-fibrotic proprieties. The M2 activation is first of all mediated by IL-4 and IL-
13 produced by Th-2 cells. 
M2 macrophages can be subdivided into 4 subgroups: 
M2a: activated in response to IL-4 and IL-13, which express high levels of 
mannose receptor (MR or CD206), secrete pro-fibrotic factors, fibronectin, 
insulin-like growth factor, and transforming-growth factor β (TGFβ). 
M2b: induced upon combined exposure to TLR ligands or IL-1 receptor 
agonists. 
M2c: triggered by IL-10 and glucocorticoids, together with the M2b type, are 
defined as “regulatory macrophages”M2d: induced by co-stimulation with 
TLR and adenosine A2A receptor agonists. They are characterized by high 
levels of IL-10 and vascular endothelial growth factor (VEGF) and low level of 
TNF and IL-12{{8977 Colin,S. 2014}}.  
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In the atherosclerotic plaque M1 and M2 macrophages represent 
respectively, the 40% and the 20% of total atherosclerotic lesion 
macrophages in mice{{8978 Kadl,A. 2010}}. 
Metalloproteinases  
Metalloproteinase are enzymes that need metal for their catalytic 
mechanism; usually this metal is zinc ion, but some use cobalt.  They divided 
into two groups based on their capacity to cleave or not cleave the terminal 
petidic bond and consequently to generate monomers; exopeptidases have 
this characteristic, while endopetidases cleave only the non-terminal peptide 
bond. 
Matrix metalloproteases and ADAM proteins belong to the endopeptidases 
group.  There are at east 23 structurally related matrix metalloproteinases that 
share a similar Zn2+ -based catalytic activity, and 24 genes (MMP-23 is 
duplicated).  Most of them are secreted, except for six membrane-type, 
which are located on the cell surface{{8979 Newby,A.C. 2007}}. 
MMPs have some common substrate to which they bind with different 
efficacy.  These substrates are: 
- ECM proteins (including collagen types I, II, III, IV, V, VI, VII, VIII, IX, X, XIV) 
- Laminin 
- Fibronectin 
- Elastin 
- Entactin 
- Vitronectin 
- Myelin basic protein  
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- Aggrecan 
- Tenascin 
- Gelatin I 
- Fibrillin 
MMPs are also able to cleave a number of non-matrix substrate, including 
plasminogen, fibrin and fibrinogen, E-cadherin, casein, MCP-3 and certain 
pro-cytokines such as membrane-bound TNFα and pro-TGFβ{{8980 
Ωεβστερ,Ν.Λ. 2006}}.. 
The degradation of extracellular matrix is an important step in development, 
morphogenesis, tissue repair and remodelling{{8981 Nagase,H. 2006}}, but 
uncontrolled ECM degradation is involved in multiple disease such as arthritis, 
nephritis, cancer, encephalomyelitis, chronic ulcers, fibrosis etc. 
Their expression is transcriptionally controlled by inflammatory citochines, 
growth factors, and hormones. 
MMPs are synthetized as zymogens in the rough endoplasmic reticulum and 
secreted via endosomal pahway; they are then activated in the cytoplasm 
by the removal of a pro-petide and inhibited by two major types of 
endogenous inhibitors: α-macroglobin and Tissue Inhibitor of 
metalloproteinases (TIMPs). 
α-macroglobin is a plasma glycoprotein that inhibits most proteinases 
entrapping them into the macroglobulin.  TIMPs inhibit most of MMPs and 
some ADAMs.  Selected MMPs are inhibited also by other proteins: MMP-2 for 
example is inhibited by the secreted form of β-amyloid precursor protein and 
by the C-terminal fragment of pro-collagen C-proteinase enhancer protein, 
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while RECK (a glycoprotein that suppressed angiogenesis) inhibits MMP-2, 
MMP-9 and MMP-14{{8981 Nagase,H. 2006}}. 
A typical MMP consists of a pro-peptide of about 80 amino acids, a catalytic 
metalloproteinase domain of about 170 amino acids, a linker peptide of 
variable lengths (also called the ‘hinge region’) and a hemopexin (Hpx) 
domain of about 200 amino acids. Gelatinase A (MMP-2) and gelatinase B 
(MMP-9), have three repeats of a fibronectin type II motif in the 
metalloproteinase domain. 
 
Figure 6. General structure of MMPs.  
Uncontrolled ECM remodelling of the myocardium and vasculature are 
present in CVD, such as atherosclerosis, left ventricular hypertrophy, heart 
failure, aneurysm{{8981 Nagase,H. 2006}}.  
As mentioned before, plaques rupture is the main cause of myocardial 
infarctions and strokes{{8979 Newby,A.C. 2007}}.  MMPs have a dual effect on 
the plaque: on one side, they weaken the cap and promote rupture, on the 
other side, MMP-2, MMP-9 and MMP-14 facilitate migration and proliferation 
of smooth muscle cells, which promote fibrous cap stability.  
 
Metalloproteinase-9 production in monocyte and macrophages 
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Peripheral blood monocyte do not express high levels of MMPs, however 
attachment to extracellular matrix or to plastic leads to an up-regulation of 
MMP-9, -10, -14 and -19{{8979 Newby,A.C. 2007}}, which, for MMP-9 and -14, 
occurs also during monocytes to macrophages transformation, and promote 
cell invasion through the intima. 
Exposure of human monocyte-derived macrophages to LPS, TNF-α, or ox-LDL 
up-regulates MMP-1 through NF-kB (Chase, 2002) and MMP-14 via serum-
amyloid A activating factor 1 (Ray, 2004); MMP-3 is regulated via NF-kB but 
mediators remain unclear.  These MMPs are involved in the early 
atherosclerosis and MMP-1 and -3 are selectively up-regulated in foam cells 
compared to normal macrophages. 
CD14+ monocytes expresses most of the 23 MMPs, with a preference for 
MMP-1, -3, -9, -10, -14, -19, -25, but also MMP-2 and -17 are represented. 
MMP-9, also called gelatinase B or type IV collagenase, is a 92kDa in the 
latent form and after the removal of the propeptide became an 86kDa.  It is 
able to degrade collagen IV, V, VII, X and XIV. It is not constitutively 
expressed and experimental conditions may influence its basal level, for 
example cellular adherence leads to higher level of MMP-9.  It can be 
produced free or complexed to TIMP.  The balance between MMP and TIMP 
decide whether it is activated. Together with MMP-8, it is stored in intracellular 
granules and, therefore, can be rapidly released independently of mRNA 
synthesis. 
MMP-9 is down regulated in monocytes after stimulation with INFγ and LPS, 
while it is up-regulated in the transition between monocytes and monocyte-
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derived macrophages (MDM), and after 10-days culture there is an increase 
of 25-fold for MMP-9 and a 9-fold increase for MMP-2.  M-CSF increases 5-fold 
in MMP-9 expression in freshly isolated monocytes. 
MMP-9 is involved in monocyte migration for example in response to 
chemoattractants. 
Positive inducers of MMP-9 in monocytes are: 
• MCP-1 
• HIV-1 Tat  
• Lectins 
• PMA 
• Endotoxin 
• IL-1β 
• Prostaglandin E2 
• Chemokines (RANTES/CCL5, RANTES/CCR1) 
• Citokines (TNFα and GM-CSF) 
Negative regulation is performed in macrophages by: 
• IL-4 
• IL-10 
• INFβ 
• INFγ 
• TGFβ 
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MMPs designations and substrate{{8980 Webster,N.L. 2006}} .   
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As the production/inhibition of MMPs is strictly regulated by several molecules, 
the results obtained using a monocytic cell-line do not necessarily reflects 
data obtained in primary cells. 
Monocyte stimulation with LPS and proinflammatory cytokines leads to 
induction of a number of MMPs, including MMP-1, -9, -2, -3; MMP-1 degrades 
fibrillar collagen I, II and III into gelatin which is further degraded by MMP-9, 
contributing to ECM degradation during inflammation.  
MMPs have an important role in modulating immune responses via specific 
cleavage of pro-sequences in chemokines and citokines. 
Regulation of MMP expression is influenced by direct contact of monocytes 
and macrophages with other cell types in various tissues and with matrix 
components{{8980 Webster,N.L. 2006}}. 
 
Metalloproteinases in atherosclerotic plaques 
High inflamed atheromatous plaques show increased global MMP activity 
(Choudhary 2006) and level of MMP-1, MMP-3, MMP-8, MMP-9 are higher in 
atheromatous than in fibrous plaques{{9016 Sukhova,G.K. 1999; 9017 
Sluijter,J.P. 2006; 9019 Orbe,J. 2003}}: MMP-9 were found in macrophages rich 
of oxidized LDL{{9021 Hua,Y. 2009}}; moreover, MMP-9 knock-out mices 
develop a reduced atherosclerosis{{9020 Luttun,A. 2004}}. 
In humans, the plaque fibrous cap prone to rupture also have increased 
MMP-8, -11, -14 and -16. Metalloproteinases-1, -2, -8, -13 and -14 can cleave 
stranght-giving fibrillar type-1 and type III collagens. Indeed MMP-1 and -13 
co-localize with cleaved collagens in plaques. 
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MMP-9 and -12 fragment elastin, whereas MMP-3 and -7 degrade cleaved 
collagens and proteoglycan core proteins. 
MMP-2 is increased in fibrous more than in atheromatous plaques, so not all 
MMPs are marker of plaques inflammation. 
 
Mineralocorticoid receptor (MR) 
 
Structure 
The MR is a member of the steroid receptor family of hormone activated 
transcription factors, codified by the NR3C2 gene that is located on 
chromosome 4q31.1-31.2{{8982 Fan,Y.S. 1989}}. MR displays a modular 
structure comprising several separate domains with specific functions{{8983 
Arriza,J.L. 1987}}.  
The N-terminal domain of the MR contains an autonomous activation 
function (AF-1) that is considered to be constitutively active{{8984 
Rupprecht,R. 1993}} ; Fuse et al., 2000) and plays a key role in the interaction 
with transcriptional coregulators{{8985 Tallec,L.P. 2003}}and with the ligand-
binding domain (LBD){{8988 Rogerson,F.M. 2003}}.  The central DNA-binding 
domain is composed of two zinc-finger structures that are involved in DNA 
binding and receptor homodimerization (Liu et al., 1996).  By definition, the 
LBD is involved in ligand binding (Fagart et al., 1998), but also in the 
interaction with the heat shock protein 90 and transcriptional 
coactivators{{8990 Couette,B. 1998; 8998 Hellal-Levy,C. 2000}} and harbors a 
ligand-dependent activation function, AF-2{{8991 Nemoto,T. 1993}}. 
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In the absence of the ligand, MR is predominantly located in the 
cytoplasm{{8992 Fejes-Toth,G. 1998}}.  It is associated with a multiprotein 
complex composed of heat shock proteins and immunophilins{{8993 Rafestin-
Oblin,M.E. 1989}}.  Heat shock protein 90 maintains the MR in an inactive state 
and in a ligand-binding–competent state{{8990 Couette,B. 1998}}.  Binding of 
aldosterone to the MR induces changes in the receptor conformation{{8995 
Trapp,T. 1995; 8996 Couette,B. 1996}} that trigger the translocation of the 
receptor into the nucleus{{8992 Fejes-Toth,G. 1998}}, the recruitment of 
transcriptional coactivators{{8998 Hellal-Levy,C. 2000}}, dimerization of the MR 
and interaction with DNA sequences located in regulatory region. 
 
Function 
MR is a receptor with equal affinity for mineralocorticoids and glucocorticoids 
and is expressed in many tissues, such as the kidney, colon, heart, central 
nervous system (hippocampus), brown adipose tissue and sweat glands.  In 
epithelial tissues, its activation leads to the expression of proteins regulating 
ionic and water transports (mainly the epithelial sodium channel or ENaC, 
Na+/K+ pump, serum and glucocorticoid induced kinase or SGK1) resulting in 
the reabsorption of Na+, and as a consequence an increase in extracellular 
volume, increase in blood pressure, and an excretion of K+ to maintain a 
normal salt concentration in the body. 
 
The RAAS (Renin-Angiotensin-Aldosterone System) regulates the electrolyte 
balance and blood pressure.  In response to decreasing blood pressure the 
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kidney release rennin, which cleaves angiotensinogen; thanks to the 
Angiotensin Converting Enzyme (ACE), the angiotensin II is active and can 
promote aldosterone release through its receptor AT1R in the adrenal.  In the 
kidney, aldosterone binds the MR to enhance re-absorption of Na+ and 
water, thus increasing blood pressure. 
The MR can be activated by mineralocorticoids such as aldosterone (or 
deoxycorticosterone in rodents) as well as glucocorticoids like cortisol, with 
equal affinity.  Since cortisol is 100-1000 fold more concentrated in the blood 
steam, the MR is mainly occupied by glucocorticoids. 
In sodium-responding cells (kidney, colon), the MR is "protected" from 
glucocorticoids by 11-beta-dehydrogenase isozyme 2 (11-β-hydroxysteroid 
dehydrogenase 2; 11ß-HSD2) an enzyme co-localized with the MR, which 
inactivetes cortisol to cortisone.   
The enzyme is also expressed in non-epithelial cells, including vascular smooth 
muscle cells and endothelial cells, while cardiomyocytes do not. 
Activation of the MR by binding of its ligand aldosterone, results in its 
translocation to the cell nucleus, homodimerization and binding to hormone 
response elements present in the promoter of some genes.  This results in the 
complex recruitment of the transcriptional machinery and the transcription 
into mRNA of the DNA sequence of the activated genes. 
 
Aldosterone, CVD and atherosclerosis 
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Compelling evidence exists that aldosterone promote cardiac fibrosis, 
hypertrophy and cell death with a strong association with inflammation and 
oxidant signaling. (He, Anderson, Cell; Rocha; Weber and Brethe).  
Primary aldosteronism (PA) is the most common form of secondary 
hypertension (PAPY, JACC, 2006); the two major causes are aldosterone-
producing adenomas and bilateral adrenal hyperplasia(Rossi Nat Rev 
Endocrinol).  Patients with PA have a significant higher risk of nonfatal 
myocardial infarction, atrial fibrillation and stroke compared with age, sex 
and blood-pressure matched essential hypertensives (Zennaro MC, 
hypertension, 2012) (Rossi, Funder TEM). 
 
Figure 6. Role of MR and aldosterone in different cell types involved in 
atherosclerosis. 
 
 
The heart is exposed to several sources of ROS (NADPH oxidase, 
mitochondrial enzymes, xanthine oxidase and NOS), and aldosterone is able 
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to generate oxidative stress through mechanisms not completely understood 
yet.  Recent studies by He{{8965 He,B.J. 2011}} identified the Ca2+/calmodulin 
dependent protein kinase II (CaMKII) as a direct downstream target of 
oxidation by NADPH-derived ROS mediated by aldosterone.   Activated 
CaMKII in turn stimulates an increase in MMP-9 action to promote cardiac 
rupture driving myocardial infarction. 
The same authors showed that CaMKII is also activated in myocytes by 
aldosterone through the MR pathway and is involved in the early 
pathological effects of aldosterone after myocardial infarction, when both 
CaMKII and ROS are elevated. 
 
 
 
 
 
 
 
 
 
Figure 7. Proposed model for MI + Aldo-induced CaMKII activation leading to 
myocardial rupture. In the acute post-MI setting, ox-CaMKII leads to MMP-9 
up-regulation to accelerate matrix breakdown, leading to cardiac rupture 
and premature death. MsrA reduces ox-CaMKII to prevent Mmp9 expression 
and protect against post-MI cardiac rupture{{8965 He,B.J. 2011}}.  
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Animal studies demonstrated a clear role of aldosterone as inducer of 
atherosclerosis in mices{{9022 Gamliel-Lazarovich,A. 2010; 9006 Keidar,S. 2004; 
9023 Keidar,S. 2003; 9024 Suzuki,J. 2006}}, rabbits{{9025 Van Belle,E. 1995; 9027 
Imanishi,T. 2008}} and monkeys{{9028 Takai,S. 2005}}. 
In humans, studies{{9029 Ivanes,F. 2012; 9030 Hillaert,M.A. 2013; 9031 Beygui,F. 
2006}} evidenced that high plasma aldosterone levels are associated with a 
worse prognosis for patients with stable coronary atherosclerosis or acute 
coronary syndrome. Theraphy with antagonist of MR (MRA) have a positive 
effect in patients with coronary atherosclerosis with or without previous 
myocardial infarction{{9032 Rossignol,P. 2011}}. 
 
Galectin -3 and atherosclerosis 
Galectin-3 (Gal-3) belongs to a family of soluble β-galactoside binding 
lectins1 that reside in the nucleus and cytoplasm of several cell types, as well 
as in the extracellular space.  It has multiple actions that can be relevant for 
promoting vascular damage and cardiovascular fibrosis. 
Accordingly, in patients with heart failure plasma Gal-3 level has been shown 
to be the best short-term predictor of events, thus leading to incorporation of 
this measurement in the current American Heart Association heart failure 
guidelines for risk stratification purposes of such patients.12 
Galectin-3 enhances monocyte interleukin-10 production to a TLR2/1 ligand; 
furthermore, galectin-3 diminished monocyte to dendritic-like cell 
differentiation and T-cell antigen presentation{{9033 Chung,A.W. 2013}}. 
Studies have shown that of Gal-3 is implicated in a variety of processes 
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associated with heart failure, including myofibroblast proliferation, 
fibrogenesis, tissue repair, inflammation, and ventricular remodelling. 
Some actions of Gal-3, as monocytes chemoattraction, enhancement of 
phagocytosis, and induction of vascular smooth muscle cells proliferation,7 
can play an important role in atherogenesis{{9034 Maiolino,G. 2015}}.  In the 
Genetic and ENvironmental factors In Coronary Artery disease(GENICA) 
study, which enrolled high cardiovascular risk patients referred for coronary 
angiography for suspected coronary artery disease (CAD), plasma Gal-3 
levels predicted cardiovascular deaths and events during long-term follow-
up after adjustment for many other cardiovascular risk factors and potential 
confounders. 
 
MR in immune cells  
The extra-renal effects of MR are clearly involved in CVD, and the 
involvement of inflammation in its initiation and progression is emerging.  A 
direct role of MR in immune cells is emerging, albeit not fully understood.  
Barish et al. In 2005 showed that 28 of 49 known nuclear receptor are 
expressed in mice macrophages; 9 of 12 known endocrine receptors are 
expressed and they included GR, MR, oestrogen receptor α (ERα), 
progesterone receptor, vitamin D receptor, thyroid receptors α and β, and 
retinoic acid receptor α and γ {{8974 Barish,G.D. 2005}}. The localization of 
glucocorticoid receptor in the immune system is distinct, reflecting their 
specific and opposing role: thymus for example expresses only GR (at one of 
the highest level in the body), while spleen expresses both GR and MR. 
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The classical and well characterized macrophages activators LPS or INF-γ 
induced a distinct temporal gene expression profile for each of the nuclear 
receptor in macrophages; LPS stimulation increased GR expression fivefold 
over baseline after just 4 hours, whereas MR gene expression was completely 
suppressed, supporting the well described and potent anti-inflammatory 
action of GR signalling{{8974 Barish,G.D. 2005}}.  Furthermore, the reduced MR 
expression is consistent with studies demonstrating the pro-inflammatory role 
of MR signalling in non-epithelial tissues (Rocha 2002, Young 2003). In contrast, 
INFγ induced a sustained fourfold increase of both receptors in 
macrophages{{9002 Rickard,A.J. 2009}}. Rickard et Young in 2009{{9002 
Rickard,A.J. 2009}} concluded that the immunostimulatory effects produced 
by low-corticosterone concentrations are mediated via MR signalling 
whereas the immunosuppressive effects of high corticosterone are produced 
through GR. 
Administration of MRA, such as eplerenone or spironolactone, reduces 
macrophages accumulation in a number of disease models including 
peritoneal fibrosis (Nishimua et al 2008), myocardial infarction (Fraccarollo 
2008) and vascular inflammation induced by angiotensin II (Neves 2005) and 
aldosterone (Rocha 2002). As demonstrated by Calò et al. (2004), 
aldosterone enhances inflammatory and oxidative stress markers such as 
p22phox and PAI-1 in human monocytes; moreover it was reported to 
increase oxidative stress (in terms of enhanced ability to oxidize LDL and 
superoxide anion production) in macrophages derived from Apo-E deficient 
mices{{9006 Keidar,S. 2004}}.  
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Aldosterone activation of MR in endothelial cells specifically modulates 
ICAM-1 expression, thus promoting leukocytes adhesion. 
Mineralocorticoid/salt treatment is also associated with increased 
monocyte/macrophages infiltration and expression, of inflammatory markers 
such as osteopontin, MCP-1, IL-6, and IL-1β in the kidney{{9004 Blasi,E.R. 2003}}.  
In macrophages, due to the lack of 11βHSD2, glucorticoids may be the 
predominant MR ligand.  However, the interplay between MR- and GR-
mediated effects in these cells, as well as the role of MR in T and B 
lymphocytes remains to be explored{{9005 Bene,N.C. 2014}}.  
The role of MR in hypertension is well known, in fact MRA are active drugs 
against essential hypertension.  In experimental models with high blood 
pressure it was demonstrated that anti-hypertensive drugs reduce both 
recruitment of macrophage in heart, brain and kidney and blood pressure.  
MR seems to have a role in macrophages polarization: as reported by 
Usher{{9007 Usher,M.G. 2010}}, in mouse peritoneal macrophages treated 
with aldosterone, the MR activation resulted in increased expression of the 
M1 classical activation markers TNFα, RANTES, MCP1, IL-12, and 
spironolactone prevented the induction of these markers by LPS; furthermore, 
MR-deficient macrophages showed reduced expression of M1 markers. 
Similarly, an immortalized mouse microglial cell line, which are macrophage-
like cells of the central nervous system, MR activation with aldosterone 
potentiated LPS induction of the pro-inflammatory cytokines TNFα and IL-6 in 
a MR but not GR dependent manner (Chantong, j neuroinflammation 2002); 
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these citokines are regulated by the transcription factor NF-kB, that is in turn 
activated in macrophages in a MR-dependent manner. 
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AIM 
The primary aim of our study was to investigate the effects of aldosterone 
and mineralocorticoid receptor antagonist on the MMP-9 production by 
monocytes/macrophages. 
The following flow chart show the experimental procedure we adopted: 
 
 
 
 
THP-1Monocyte 
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MATERIALS AND METHODS 
 
Cell cultures 
Human monocytes were isolated from buffy coat by double gradient 
separation with Ficoll 1077 and Percoll (2 separate centrifugation 400x g 30’ 
without brake and accelerator); cells were rinsed in RPMI 1640 supplemented 
with L-glutamine (1%), antibiotic-antimycotic solution (1%), and 2% of heat-
inactivated foetal bovine serum (FBS), counted by trypan blue exclusion 
method, and are allowed to adhere to the plate for 1 hour at 37°C. All 
reagents were purchased from Sigma Aldrich, Italy. 
Cells were seeded at the concentration of 2x106 cells in a 24-well plate for 
monocyte, and at 5x105 cells/well to obtain macrophages, then washed 3 
times with adhesion and stimulation medium, in order to eliminate all non 
adherent cells (lymphocytes). 
Monocytes are stimulated immediatly after separation, while GM-CSF was 
used to obtain macrophages (Miltheniy Biothech) in RPMI 20% FBS for 1 week, 
with a partial change of medium at day 4. 
 
THP-1 is a human monocytic cell line derived from an acute monocytic 
leukemia of 1-year-old male patient (Tsuchiya S, Yamabe M, Yamaguchi Y, 
Kobayashi Y, Konno T, Tada K (August 1980). "Establishment and 
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characterization of a human acute monocytic leukemia cell line (THP-1)". Int. 
J. Cancer 26 (2): 171–6. doi:10.1002/ijc.2910260208) 
THP-1 cell line were grown in suspension in RPMI 1640 medium supplemented 
with 10% FBS, L-glutamine (1%), antibiotic-antimycotic solution (1%). 
To obtain THP-1 macrophages, we added 100nM PMA (phorbol 12-myristate 
13-acetate, Sigma Aldrich) for 72 hours; after this period, the majority of cells 
are attached to the well.  
Medium was discarded and replaced with new fresh medium without PMA 
for 3-6 days (resting time). 
To stimulate cells for zymography, we added stimulus in RPMI medium without 
FBS or in presence of  Nutridoma (Roche/Sigma Aldrich), a chemical 
supplement that can completely replace serum in cell culture media. 
 
Dose-response curve of Aldosterone 
THP-1 macrophages and human macrophages were obtained as described 
before. The aldosterone stimulus is placed in RPMI without FBS at decreasing 
concentrations (10-5, 10-6, 10-7, 10-8, 10-9M) and samples were collected after 
6-16-24-48 hours. 
After this time, the surnatant was centrifuged (4,7xg x 5’) to eliminate cells in 
suspension, and surnatant were collected at -80°C until use. 
 
Other cell stimulations 
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Canrenone (Doppel Farmaceutici) was added at a concentration 100-fold 
higher than that of aldosterone and put 30 minutes before, to allow the 
occupancy of the MRs. 
Lipopolysaccharide from Escherichia coli (Sigma Aldrich) was used at 
concentration of 100 ng/ml. 
Modified Citrus Pectin (PectaSol-C, ecoNugenics) was dissolved in PBS at final 
concentration of 0.5 mg/ml. 
 
RT-PCR 
Total RNA was extracted from cells using the High Pure RNA Isolation Kit 
(Roche).  One µg of total RNA were reverse transcribed with iScript™ Reverse 
Transcription Supermix for RT-qPCR (BioRad; Milan, Italy) in a final volume of 20 
µl. The mRNA was measured with a real time qRT-PCR with universal 
ProbeLibrary probes in the LightCycler 480 Instrument (Roche; Milan Italy).  
The expression was calculated applying DDCt method relative to actin or 18S 
used as an internal control. 
 
Zimography 
To investigate the gelatinolitic activity of MMP-9 in response to aldosterone, 
we used zymography, a semi-quantitative electroforetic running, performed 
in a 8% gel containing gelatin as substrate, under non-reducing conditions. 
Equal volumes of surnatant proteins were used for each sample. 
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After the running, the gels were rinsed in 2.5% Triton X-100 (Sigma Aldrich) 
2x30’ to remove SDS, followed by incubation at 37°C overnight in developing 
buffer (Tris 100 mM, NaCl 400 mM, CaCl2 20 mM). 
Gels were then stained (0.5% Comassie Brillant Blue, Sigma Aldrich) for 30' and 
destained with a destaining solution (methanol 5%, acetic acid 7%); areas of 
enzymatic activity appeared as clear bands over the blue background.  
Band intensity were measured with VersaDoc Imaging System (Biorad) and 
the MMP9 activity was calculated as ratio between the treated and non-
treated samples; the quantification was performed with ImageJ (NIH, U.S). 
 
Western Blot  
MR protein expression in THP-1 cells was evaluated by Western Blot analysis; 
cells were homogenized in lysis buffer (Thermo Scientific, Italy) and protein 
concentration was determined in the soluble supernatant with BCA (Thermo 
Scientific, Italy).  
Lysate fraction (50 µg) was separated in a poliacrylamide gel and then  
electroblotted onto nitrocellulose membrane (Hybond ECL-Amersham 
Biosciences Europe, Germany).  The membranes were blocked for 1h at room 
temperature in 5% non-fat dry Blocking Milk (Roth) and thereafter incubated 
overnight at 4°C with a primary mouse monoclonal antibody against human 
MR (1:100 dilution) (a kind gift from Prof. Celso Gomez Sanchez){{9038 
Gomez-Sanchez,C.E. 2011}}). Blots were analyzed with the QuantityOne 
software. 
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RESULTS 
 
THP-1 monocytes and differentiation into macrophages  
Phorbol 12-myristate 13-acetate (PMA) was used to differentiate THP-1 
monocytes into macrophages through the activation of Protein Kinase C 
(PKC).  The different cells phenotype was  detected by their different 
features, entailing a large, round cell morphology and growth in suspension 
of THP-1 monocytes and a “star-like” shape with adherence to the well 
plastic of THP-1 macrophages.  
THP-1 monocytes differentiation was induced through exposure different PMA 
concentrations, i.e. 50 nM, 75 nM, 100 nM, 200 nM, for 24 hours. 
To verify the cells transformation they were analyzed by means of flow 
cytometry (Fluorescence Activated Cell Sorting, FACS); due to the cost of this 
technique, we decided to test THP-1 monocytes and THP-1 + PMA 100 nM.  
Flow cytometry allows to scatter the cells by dimension and granulosity; after 
PMA treatment for 24 hours the cells began to show the phenotypic transition 
toward macrophages (Figure 1A), although a relevant amount of them 
remained in suspension.  
Furthermore, the sorting based on HLA-DR antibody discrimination evidenced 
a difference between untreated THP-1 and THP-1 PMA10-7M-treated 
monocytes: after 24 hours this marker was expressed by 57% of monocytes 
and by only the 27% of PMA10-7M-treated cells (Figure 1B). 
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Based on these preliminary results, the time of PMA with different PMA 
concentrations (50 nM, 75 nM, 100 nM, 200 nM) stimulation was extended to 
different periods (24, 48 and 72 hours).  The optimal PMA concentration and 
stimulation interval selected were 100 nM for 72 hours, which guaranteed 
adherent and healthy cells, whereas at lower PMA concentration the 
adherence was not complete, and at higher concentration the cells 
displayed unhealthy features, evidenced by the presence of cell debris and 
shape dissimilarities.  
The gene expression of PPARγ was evaluated at RT-PCR to confirm the 
differentiation of monocytes into macrophages according to the method 
reported by Maeß (Selection of reliable reference genes during THP-1 
monocyte differentiation into macrophages, Stefanie Sendelbach and 
Stefan Lorkowski).  This is based on the premise that PPARγ is the least stable 
gene in the transition of THP-1 monocytes toward macrophages; hence its 
gene expression was found to be very different between THP-1 macrophage 
and THP-1 monocytes.  For these reasons the gene expression of PPARγ was 
determined to confirm the shift from monocytes to macrophages evidenced 
at morphological examination.  As shown in figure 2, PPARγ gene expression 
increases in a concentration-dependent manner, confirming that the 100 nM 
concentration of PMA leads to an increased transition of the cells into 
macrophages. 
 
THP-1 monocytes/macrophages expression of MR 
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Preliminary to the investigation of the effects of aldosterone on 
monocyte/macrophages, it was initially necessary to seek for the expression 
of MR in these cells.  
Gene expression studies (RT-PCR) data evidenced that THP-1 monocytes 
show lower expression of MR compared to THP-1-derived macrophages 
treated with 100 nM PMA for 72 hours: MR gene expression was 1.63 ± 0.26 (p 
= 0.008) fold more expressed compared to THP-1 monocytes (Figure 3).  
The western blot (Figure 4) data confirmed that THP-1 monocytes have lower 
expression of MR compared to THP-1-derived macrophages: the stimulation 
performed included three different concentrations of PMA for 72 hours; after 
this time of PMA stimulation the MR protein expression was significantly higher 
at PMA concentration of 100 nM compared to THP-1 monocytes (4.11 ± 0.35 
p = 0.001).  Thus, we choose this experimental setting to induce THP-1 
differentiation in all further experiments. 
 
Demonstration of aldosterone activity through the MR on THP-1 macrophages 
To demonstrate that THP-1-derived macrophages are responsive to 
aldosterone MR-mediated effects, FKBP51, a 51KDa FK506 binding protein 
whose expression is known to be induced by aldosterone, was determined. 
THP-1-derived macrophages showed a significant increase of FKBP51 gene 
expression (p = 0.002) with increasing concentrations of aldosterone, as 
assessed by RT-PCR (Figure 5).  
  
Metalloproteinase-9 activity in THP-1 monocyte 
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After demonstrating that THP-1 monocytes express the MR, these cells were 
stimulated with aldosterone for 24 hours and surnatants were collected to test 
MMP-9 activity. As shown in Figure 6, at zymography THP-1 monocytes did not 
show any increase in MMP-9 activity in response to aldosterone.  In particular 
there were no differences between the band density of control THP-1 
monocytes (treated with vehicle) and aldosterone-treated cells.  
 
MMP-9 activity in THP-1 macrophages 
To test the effects of aldosterone on MMP-9 activity induced by THP-1 
macrophages a dose- (aldosterone concentration 10-5 M, 10-6 M, 10-7 M, 10-8 
M, 10-9 M) and time-response (5, 16, 24, and 48 hours) curve were completed. 
As shown in Figure 7, at higher aldosterone concentrations, i.e. 10-5M and 10-
6M, the stimulation effect on MMP-9 activity occurs early in the time-course 
analysis, between 5 and 24 hours.  At variance, lower aldosterone 
concentrations, i.e. 10-8M and 10-9M, the increase in MMP-9 activity occurs 
later, with a significant peak at 16 and 48 hours (aldosterone 10-8 M for 16 
hours, p = 0.003 vs baseline, and aldosterone 10-9M at 16 and 48 hours, p ≤ 
0.001). Stimulations of cells for zymography must be performed in serum-free 
medium, which is a stressful condition and when too protracted, i.e. 48 hours, 
induced THP-1 cells detachment from the plate.  Thus, 48 hours stimulations 
were excluded for further experiments.  
 
MMP-9 activity on human macrophages 
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The same experiments performed on THP-1 cell line were repeated on human 
monocytes differentiated into M1 subtype macrophages, using GM-CSF.  
FKBP51 gene expression was tested before starting the dose-response curve 
experiments to verify that the human cells are responsive to aldosterone. 
Compared to macrophages vehicle-treated, the gene expression of FKBP51 
raised in a concentration dependent manner, as expected, with a 5.25 ± 0.30 
(p < 0.0001) fold increase for cells stimulated with aldosterone 10-5M (Figure 
8). 
 
Considering the aforementioned data obtained with the THP-1 cell line, we 
tested MMP-9 activity on human macrophages, in a simplified dose- and 
time-response curve, focusing on lower concentrations of aldosterone (10-7 M, 
10-8 M, 10-9 M) for 2, 6 and 24 hours.  
Gene expression data (Figure 9, panel A) showed a significant increase of 
MMP-9 expression after 2 hours of aldosterone at 10-7M and 10-8M 
concentrations (2.03 ± 0.26 and 2.05 ± 0.26 fold change vs. control, 
respectively; p < 0.001).   Only at 6 hours 10-7M aldosterone showed  higher 
MMP-9 expression compared to control (1.71 ± 0.25, p = 0.01).  Treatment of 
human macrophages with aldosterone for 24 hours did not result in an MMP-9 
gene expression increase compared to control. 
 
After stimulation of macrophages with decreasing concentrations of 
aldosterone for 2 hours there was no increase in MMP-9 activity at 
zymography, except for a slightly increased activity at lower aldosterone 
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concentration (10-9M).  After stimulation for 6 hours MMP-9 activity showed 
high variability at higher aldosterone concentrations, which was borderline 
significant at 10-7M (1.26 ± 0.12 p = 0.05).  Finally, after 24 hours of stimulation 
MMP-9 activity was significantly higher at lower aldosterone concentrations, 
i.e. 1,23 ± 0,07 fold increase compared to vehicle-treated cells (p = 0.006) at 
aldosterone 10-8 M and 1,36 ± 0,08 fold increase at aldosterone 10-9 M (p < 
0.001) (Figure 9, panel A). 
Based on these data, we choose to investigate the effect of aldosterone 10-7 
exposure for 2 and 6 hours. Figure 10 shows the gene expression (panel A) 
and zymography (panel B) of MMP-9 in presence of the MRA canrenone. 
RT-PCR shows a borderline significance in reduction, both at 2 and 6 hours, in 
presence of canrenone respect to aldosterone-induced MMP-9 gene 
expression (p = 0.18 and p = 0.08 at 2 and 6 hours, respectively). 
  
At zymography, canrenone appear to have a small inhibitor effect on MMP-9 
activity both at 2 and 6 hours (Figure 10, panel B). 
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DISCUSSION  
 
Atherosclerosis is initiated by stimuli, which lead to endothelial dysfunction 
with consequent expression of adhesion molecules and increased 
permeability to macromolecules.  In these conditions LDLs enter the 
endothelium and are oxidized by resident vascular cells, promoting 
monocytes recruitment and transformation into macrophages, which can 
further promote oxidation of LDLs.  Completely oxidized LDLs are recognized 
by macrophage scavenger receptors and internalized with consequent 
foam cells formation and accumulation inside the plaque together with other 
inflammatory cells, which promote plaque rupture through the release of 
matrix metalloproteinases and other collagenolytic enzymes (Maiolino, 
Rossitto, Caielli, Bisogni The Role of Oxidized Low-Density Lipoproteins in 
Atherosclerosis: The Myths and the Facts, 2013). 
There is currently growing attention on the aldosterone role in atherosclerosis 
development, which was postulated based on animal and clinical data. In 
fact, aldosterone promotes endothelium dysfunction, mainly through 
generation of vascular ROS (Spironolactone Improves Angiotensin-Induced 
Vascular Changes and Oxidative Stress, Agostino Virdis, Mario Fritsch Neves, 
Farhad Amiri, Emilie Viel, Rhian M. Touyz, Ernesto L. Schiffrin, J Hypert 2002; 
Calo; Keidar), vascular inflammation (Am J Physiol Heart Circ Physiol. 2002 
Nov;283(5):H1802-10. Aldosterone induces a vascular inflammatory 
phenotype in the rat heart. Rocha R1, Rudolph AE, Frierdich GE, Nachowiak 
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DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA), and macrophages 
polarization toward the inflammatory phenotype (M1) (Usher, J Clin Invest 
2010v120p3350). Furthermore, animal studies demonstrated that aldosterone 
plays an important role in atherosclerosis in mice (gamliel-lazarovich J 
Hypertens 2010v28p1900; keidar circ; keidar J Cardiovasc Pharmacol 
2003v41p955, suzuki Arterioscler Thromb Vasc Biol 2006v26p917), rabbits (Van 
Belle Cardiovasc Res. 1995 Jan;29(1):27, Imanishi Hypertension 2008v51p734) 
and monkeys (takai Hypertension 2005v46p1135).  These findings were 
corroborated by studies on humans showing that patients with stable 
coronary atherosclerosis{{9029 Ivanes,F. 2012}} or with acute coronary 
syndrome{{9031 Beygui,F. 2006}} had a worse prognosis with raising plasmatic 
levels of aldosterone. Clinical non-randomized studies evidenced the positive 
effect of mineralocorticoid receptor antagonists (MRA) in patients with 
coronary atherosclerosis with or without previous myocardial infarction{{9032 
Rossignol,P. 2011}}.  These data were confirmed by recently published 
randomized clinical trials demonstrated in patients with ST elevation 
myocardial infarction MRA decreased events (montalescot Eur Heart J 
2014v35p2295) and mortality (ALBATROSS study Esc 2015).  In conclusion, 
despite compelling evidences of the relevant role played by aldosterone in 
atherosclerosis development the mechanisms responsible for these effects 
have been elusive. 
 
Therefore, to investigate the effects of aldosterone a cellular model entailing 
monocytes/macrophages was selected, based on their crucial role in 
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atherosclerosis. To increase the robustness of the results, we conducted the 
experiments both on THP-1 cell line and human cells. 
After confirming the expression of the MR in THP-1-derived and in human 
macrophages, which was higher compared to monocytes, the 
responsiveness to aldosterone stimulation was demonstrated showing the 
concentration-dependent increased gene expression of FKBP51, a 
downstream effector of MR. 
 
After demonstration that aldosterone increases MMP-9 expression in 
cardiomyocytes{{8965 He,B.J. 2011}} we postulated a similar effect in 
monocytes and macrophages, where this metalloproteinase might promote 
atherosclerosis development and plaque destabilization. 
In fact, MMP-9 was found in atherosclerotic plaques{{9019 Orbe,J. 2003}} and 
in macrophages rich of oxidized low-density lipoprotein{{9021 Hua,Y. 2009}}. 
Moreover, in an animal model of atherosclerosis, ApoE-MMP-9 knock-out 
mice showed a decreased aortic atherosclerotic burden compared to wild 
type animals{{9020 Luttun,A. 2004}}.  Finally, in humans this metalloproteinase 
was associated to carotid plaque destabilization (Tan Atherosclerosis 232 
(2014) 199) and acute coronary syndrome [Tretjakovs Clin. Chim. Acta 413 
(2012) 25]. 
I first tested the MMP-9 production in response to aldosterone in the THP-1 
monocytes, demonstrating a minimal metalloproteinase production under 
aldosterone stimulation (figure 7).  Being the macrophage the effector of 
inflammatory responses in the atherosclerotic plaque I completed the 
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experiments after PMA-induced differentiation of THP-1 monocytes into 
macrophages. 
The morphological transition of the THP-1 monocytes toward macrophages 
was confirmed at FACS; among the available antibodies, we select HLA-DR 
as a marker to test the differentiation of the cells, because it was 
demonstrated as highly expressed in THP-1 monocytes compared to  THP-1-
derived macrophages (flow citometry and high-content imagining to identify 
markers od monocyte-macrophage differentistion, 2011, Dev Mittar, Rosanto 
Paramban, and Catherine McIntyre BD Biosciences). Accordingly, the 
majority of THP-1 monocytes displayed a HLA-DR+ profile, while 72% of THP-
1+PMA for 24 hours were HLA-DR-.  
 
We performed several experiments to clarify if aldosterone has a role in MMP-
9 expression and activity in macrophages. Despite the difficulties in 
quantifying zymography and the variability of PCR data, we found that MMP-
9 significantly increases in presence of aldosterone both in THP-1 cell line and 
human macrophages even if this effect is not macroscopic; aldosterone in 
fact acts on  a cell-system which is already stimulated during the transition 
between monocyte to macrophage. 
NF-kB is involved in MMP-9 production in response to LPS: it was demonstrated 
that the translocation of NF-kB into the nucleus (where it acts as 
transcriptional factor) occurs within 2 hours after LPS challenge.  Therefore we 
decided to analyse more in detail what happens with shorter time of 
incubation in dose-response and time-response experiments with human 
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macrophages.  Under these condition, we found a clear effect on gene 
expression, hence we would like to contend that: 
- NF-kB is a downstream effector of MR; 
- Canrenone decrease aldosterone effect on MMP-9, confirming its 
antagonist action on MR and consequently demonstrating that the 
aldosterone-medited MMP-9 increase is MR-dependent. 
MMP-9 activity assessed by zymography and MMP-9 gene expression appear 
to have a different timing: MMP-9 activity seems to increase at 24 hours while 
gene expression is higher between 2 and 6 hours. This point could be 
explained with the storage in granules of MMP-9, which released in response 
to a stimuli, hence not necessarily there is a relation between the gene 
/protein expression and the activity of the enzyme. 
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CONCLUSIONS 
 
In my PhD thesis I demonstrated for the first time that aldosterone induces 
matrix metalloproteinase-9 expression in macrophages, a crucial player of 
atherosclerotic plaque destabilization, and that this effect is mediated by the 
mineralocorticoid receptor. These results might explain the association 
between aldosterone and cardiovascular events in patients with stable 
coronary artery disease and the beneficial effects of mineralocorticoid 
receptor antagonists in acute ST-elevation myocardial infarction 
(montalescot Eur Heart J 2014v35p2295; ALBATROSS study Esc 2015]. Further 
studies are required to determine if a more liberal use of mineralocorticoid 
receptor antagonists might benefit patients with atherosclerosis. 
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Figure 1. 
A) Scatterplot of THP-1 monocytes in PBS (left panel) and of THP-1+ 
PMA100 nM after 24 hours of stimulation (right panel).
B) Sorting of THP-1 monocytes (left panel) and THP-1 + PMA 100 nM 24 
hours (right panel) for HLA-DR antibody.
A
B
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Figure 2: PPARγ gene expression on THP-1 
macrophages in presence of different concentration 
of PMA for 72 hours.
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Figure 3. MR gene expression in THP-1 vehicle-treated and 
PMA10-7M monocytes on THP-1 + for 72 hours 
(macrophages). 
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Figure 4. Rapresentative immunoblot of MR protein expression 
in THP-1 monocytes and THP-1 with different concentration of 
PMA, for 72 hours. 
* P ≤ 0.001vs THP-1 monocytes.
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Figure 5. FKBP51 gene expression in macrophages stimulated with 
different concentration of aldosterone.
* P ≤ 0.005 vs Vehicle
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Figure 6. Representative zymography on THP-1 monocyets surnatants and the 
corresponding bar graph with the plot of the ratio between band density of 
treated cells on band density of non-treated cells (vehicle); 
THP-1 surnatants at baseline (lane1), in presence of aldosterone 10-8M (lane 2), 
Canrenone 10-6 M (lane 3) and in presence of both (lane 4) for 24h.
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Figure 7. MMP-9 activity at different time points (5-16-24-48 hours), in 
response to decreasing concentrations of aldosterone, assessed by 
zymography.
Fold change in MMP-9 activity of THP-1 macrophages treated with 
aldosterone was measured versus THP-1 macrophages treated with 
vehicle.
# p ≤ 0.005, * p ≤ 0.001 vs Vehicle
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Figure 8. FKBP51 gene expression on human macrophages.
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Figure 9.
A)MMP-9 gene expression on human monocyte-derived macrophages in 
presence of different concentration of aldosterone.
B)Corresponding MMP-9 activity assessed by zymography.
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Figura 10.
A)  MMP-9 gene expression in presence of Canrenone (as MR 
inhibitor)
B) Corresponding MMP-9 activity
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